Share Price and Basic Stock Data
Last Updated: November 26, 2025, 6:46 pm
| PEG Ratio | 0.00 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
ANG Lifesciences India Ltd operates in the pharmaceuticals sector, focusing on the development and distribution of various medicinal products. The company’s market capitalization stood at ₹36.8 Cr, with its share price at ₹28.2. Over the past several quarters, the company’s revenue has shown significant fluctuations. For instance, sales reported for the year ending March 2023 were ₹206.82 Cr, a decline compared to ₹348.52 Cr in March 2022. The revenue for the trailing twelve months (TTM) was ₹98.27 Cr, indicating ongoing challenges in maintaining consistent sales. Quarterly sales figures illustrate this volatility, with a peak of ₹71.56 Cr in June 2022, followed by a low of ₹17.10 Cr in December 2023. This inconsistent revenue stream raises concerns regarding the company’s market positioning and operational efficiency. The drop in sales reflects a broader issue within the pharmaceutical sector, where many companies grapple with regulatory pressures and competitive pricing, impacting overall sales performance.
Profitability and Efficiency Metrics
Profitability metrics for ANG Lifesciences have been under pressure, as evidenced by the reported net profit of -₹10.34 Cr for the year ending March 2025, a significant decline from ₹39.71 Cr in March 2022. The gross operating profit margin (OPM) stood at 7.58%, reflecting a challenging cost environment. The operating profit for March 2025 was recorded at -₹1.02 Cr, showcasing the company’s struggle to convert sales into profit amid rising expenses. The interest coverage ratio (ICR) was a concerning -0.02x, indicating that the company is unable to cover its interest obligations from its earnings. Additionally, the return on equity (ROE) was reported at 13.8%, which is relatively low compared to industry standards, suggesting inefficiencies in generating shareholder returns. The cash conversion cycle (CCC) of 158.34 days further complicates the operational efficiency, indicating that the company takes a long time to convert its investments in inventory and receivables back into cash.
Balance Sheet Strength and Financial Ratios
ANG Lifesciences’ balance sheet reflects substantial weaknesses, particularly with no reported reserves and borrowings. The company’s debt-to-equity ratio stood at 1.26, indicating a high reliance on debt financing which can pose risks in a rising interest rate environment. The book value per share has declined from ₹80.81 in March 2022 to ₹48.99 in March 2025, signaling deterioration in net asset value. The current ratio was reported at 1.15, suggesting that the company is barely able to meet its short-term liabilities. Furthermore, the price-to-book value (P/BV) ratio of 0.46x indicates that the stock is undervalued relative to its book value, presenting a potential opportunity for investors. However, the negative trends in profitability and the high leverage raise red flags about the company’s financial health and sustainability. Overall, the balance sheet metrics suggest a need for strategic financial restructuring to improve liquidity and solvency.
Shareholding Pattern and Investor Confidence
The shareholding pattern of ANG Lifesciences indicates strong promoter support, with promoters holding 70.60% of the total shares, providing a degree of stability in ownership. However, the public shareholding has been relatively static, standing at 29.40%, which may reflect a lack of investor confidence in the company’s growth prospects. The number of shareholders has decreased to 6,273 as of March 2025 from a peak of 7,305 in June 2023, indicating potential disenchantment among retail investors. The absence of foreign institutional investors (FIIs) and domestic institutional investors (DIIs) further underscores the lack of external validation and support for the company. This concentrated ownership structure, while beneficial in terms of control, may limit external insights and broader market appeal, which are crucial for recovery in the stock’s performance. Investor confidence appears to be waning, reflecting concerns over the company’s ability to return to profitability and stabilize operations.
Outlook, Risks, and Final Insight
The outlook for ANG Lifesciences remains precarious, with significant risks overshadowing its potential recovery. The persistent decline in revenue and profitability raises concerns about its operational viability. The high debt levels coupled with negative earnings could hinder the company’s ability to invest in growth initiatives. On the other hand, the solid promoter stake may provide a cushion against volatility and present an opportunity for strategic restructuring. If the company can improve its operational efficiency and manage costs effectively, it may regain investor confidence. However, failure to address these financial challenges could lead to further deterioration in market perception. Future strategies may need to focus on enhancing product offerings, optimizing cost structures, and potentially seeking new markets or partnerships to diversify revenue streams. In summary, while ANG Lifesciences has strengths in ownership stability, its financial health requires urgent attention to navigate the pressing challenges ahead.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of ANG Lifesciences India Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 162 Cr. | 129 | 247/84.3 | 35.9 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.36 Cr. | 1.76 | 4.33/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,538 Cr. | 417 | 479/192 | 94.0 | 24.3 | 0.16 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 34.9 Cr. | 47.0 | 92.2/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 41.5 Cr. | 28.3 | 29.1/17.0 | 98.8 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,356.00 Cr | 1,182.92 | 52.67 | 202.40 | 0.35% | 16.24% | 14.95% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 71.56 | 58.39 | 45.17 | 31.88 | 50.61 | 29.58 | 17.10 | 34.08 | 16.18 | 32.16 | 23.91 | 17.67 | 24.53 |
| Expenses | 60.28 | 49.15 | 43.03 | 43.48 | 44.94 | 28.26 | 18.82 | 30.23 | 18.11 | 29.70 | 25.89 | 18.03 | 22.67 |
| Operating Profit | 11.28 | 9.24 | 2.14 | -11.60 | 5.67 | 1.32 | -1.72 | 3.85 | -1.93 | 2.46 | -1.98 | -0.36 | 1.86 |
| OPM % | 15.76% | 15.82% | 4.74% | -36.39% | 11.20% | 4.46% | -10.06% | 11.30% | -11.93% | 7.65% | -8.28% | -2.04% | 7.58% |
| Other Income | 0.12 | 0.20 | 0.32 | 9.20 | 0.34 | 0.33 | -0.09 | -1.49 | 1.36 | 0.36 | -0.03 | 0.75 | 0.17 |
| Interest | 3.17 | 3.20 | 2.84 | 1.11 | 1.94 | 1.96 | 1.99 | 3.44 | 1.67 | 1.87 | 1.71 | 2.05 | 1.61 |
| Depreciation | 1.88 | 1.90 | 1.92 | 2.82 | 1.94 | 1.97 | 2.02 | 1.83 | 1.51 | 1.62 | 1.84 | 1.30 | 1.45 |
| Profit before tax | 6.35 | 4.34 | -2.30 | -6.33 | 2.13 | -2.28 | -5.82 | -2.91 | -3.75 | -0.67 | -5.56 | -2.96 | -1.03 |
| Tax % | 47.24% | 39.63% | -30.43% | -20.54% | 25.35% | -10.09% | -20.96% | 23.71% | -26.13% | 61.19% | -17.99% | -34.46% | -23.30% |
| Net Profit | 3.34 | 2.62 | -1.60 | -5.03 | 1.60 | -2.05 | -4.59 | -3.60 | -2.77 | -1.07 | -4.57 | -1.94 | -0.79 |
| EPS in Rs | 2.57 | 2.02 | -1.23 | -3.85 | 1.23 | -1.57 | -3.52 | -2.76 | -2.12 | -0.82 | -3.50 | -1.49 | -0.60 |
Last Updated: August 19, 2025, 11:45 pm
Below is a detailed analysis of the quarterly data for ANG Lifesciences India Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 24.53 Cr.. The value appears strong and on an upward trend. It has increased from 17.67 Cr. (Mar 2025) to 24.53 Cr., marking an increase of 6.86 Cr..
- For Expenses, as of Jun 2025, the value is 22.67 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 18.03 Cr. (Mar 2025) to 22.67 Cr., marking an increase of 4.64 Cr..
- For Operating Profit, as of Jun 2025, the value is 1.86 Cr.. The value appears strong and on an upward trend. It has increased from -0.36 Cr. (Mar 2025) to 1.86 Cr., marking an increase of 2.22 Cr..
- For OPM %, as of Jun 2025, the value is 7.58%. The value appears strong and on an upward trend. It has increased from -2.04% (Mar 2025) to 7.58%, marking an increase of 9.62%.
- For Other Income, as of Jun 2025, the value is 0.17 Cr.. The value appears to be declining and may need further review. It has decreased from 0.75 Cr. (Mar 2025) to 0.17 Cr., marking a decrease of 0.58 Cr..
- For Interest, as of Jun 2025, the value is 1.61 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 2.05 Cr. (Mar 2025) to 1.61 Cr., marking a decrease of 0.44 Cr..
- For Depreciation, as of Jun 2025, the value is 1.45 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1.30 Cr. (Mar 2025) to 1.45 Cr., marking an increase of 0.15 Cr..
- For Profit before tax, as of Jun 2025, the value is -1.03 Cr.. The value appears strong and on an upward trend. It has increased from -2.96 Cr. (Mar 2025) to -1.03 Cr., marking an increase of 1.93 Cr..
- For Tax %, as of Jun 2025, the value is -23.30%. The value appears to be increasing, which may not be favorable. It has increased from -34.46% (Mar 2025) to -23.30%, marking an increase of 11.16%.
- For Net Profit, as of Jun 2025, the value is -0.79 Cr.. The value appears strong and on an upward trend. It has increased from -1.94 Cr. (Mar 2025) to -0.79 Cr., marking an increase of 1.15 Cr..
- For EPS in Rs, as of Jun 2025, the value is -0.60. The value appears strong and on an upward trend. It has increased from -1.49 (Mar 2025) to -0.60, marking an increase of 0.89.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 3:57 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 34.50 | 36.84 | 54.92 | 66.93 | 75.13 | 121.27 | 126.08 | 154.24 | 348.52 | 206.82 | 131.30 | 89.73 | 98.27 |
| Expenses | 29.61 | 33.72 | 50.19 | 60.43 | 67.83 | 109.63 | 113.65 | 138.91 | 282.98 | 195.15 | 121.75 | 90.75 | 96.29 |
| Operating Profit | 4.89 | 3.12 | 4.73 | 6.50 | 7.30 | 11.64 | 12.43 | 15.33 | 65.54 | 11.67 | 9.55 | -1.02 | 1.98 |
| OPM % | 14.17% | 8.47% | 8.61% | 9.71% | 9.72% | 9.60% | 9.86% | 9.94% | 18.81% | 5.64% | 7.27% | -1.14% | 2.01% |
| Other Income | 0.12 | 0.09 | 0.21 | 0.25 | 0.69 | 0.23 | 0.42 | 0.75 | 0.95 | 9.84 | -0.89 | 1.99 | 1.25 |
| Interest | 1.51 | 1.66 | 1.66 | 1.77 | 1.85 | 2.64 | 3.22 | 3.98 | 8.31 | 10.92 | 9.77 | 7.64 | 7.24 |
| Depreciation | 3.05 | 0.95 | 1.06 | 1.17 | 1.19 | 1.12 | 1.23 | 2.24 | 5.12 | 8.52 | 7.75 | 6.27 | 6.21 |
| Profit before tax | 0.45 | 0.60 | 2.22 | 3.81 | 4.95 | 8.11 | 8.40 | 9.86 | 53.06 | 2.07 | -8.86 | -12.94 | -10.22 |
| Tax % | 55.56% | 31.67% | 25.23% | 25.98% | 24.65% | 30.33% | 27.50% | 26.47% | 25.18% | 131.88% | -2.48% | -20.02% | |
| Net Profit | 0.19 | 0.40 | 1.65 | 2.82 | 3.72 | 5.65 | 6.10 | 7.25 | 39.71 | -0.66 | -8.65 | -10.34 | -8.37 |
| EPS in Rs | 0.21 | 0.43 | 1.79 | 3.07 | 2.86 | 4.35 | 4.69 | 5.58 | 30.55 | -0.51 | -6.62 | -7.92 | -6.41 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 2.61% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 110.53% | 312.50% | 70.91% | 31.91% | 51.88% | 7.96% | 18.85% | 447.72% | -101.66% | -1210.61% | -19.54% |
| Change in YoY Net Profit Growth (%) | 0.00% | 201.97% | -241.59% | -38.99% | 19.97% | -43.92% | 10.89% | 428.87% | -549.39% | -1108.94% | 1191.07% |
ANG Lifesciences India Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 9% |
| 5 Years: | -7% |
| 3 Years: | -36% |
| TTM: | 1% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 28% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 6% |
| 3 Years: | -45% |
| 1 Year: | -48% |
| Return on Equity | |
|---|---|
| 10 Years: | 12% |
| 5 Years: | 9% |
| 3 Years: | -8% |
| Last Year: | -14% |
Last Updated: September 5, 2025, 2:16 pm
No data available for the Balance Sheet data table.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 79.67 | 62.22 | 108.86 | 139.39 | 156.19 | 125.66 | 133.34 | 139.10 | 103.67 | 137.85 | 192.56 | 264.24 |
| Inventory Days | 83.99 | 84.14 | 46.81 | 44.62 | 53.41 | 27.18 | 41.03 | 67.62 | 46.29 | 92.90 | 143.34 | 227.95 |
| Days Payable | 129.49 | 129.88 | 133.28 | 163.44 | 153.96 | 90.63 | 105.80 | 158.84 | 105.16 | 153.93 | 243.56 | 333.86 |
| Cash Conversion Cycle | 34.17 | 16.48 | 22.39 | 20.58 | 55.64 | 62.21 | 68.56 | 47.88 | 44.80 | 76.83 | 92.34 | 158.34 |
| Working Capital Days | 28.25 | 18.73 | 10.23 | 14.40 | 48.29 | 39.70 | 52.60 | 47.14 | 22.05 | 27.88 | 74.97 | 71.80 |
| ROCE % | 13.65% | 16.74% | 26.04% | 29.34% | 21.90% | 23.56% | 21.92% | 19.90% | 53.78% | 8.51% | 1.78% | -3.54% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 |
|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | -9.42 | -7.65 | 0.36 | 39.39 |
| Diluted EPS (Rs.) | -9.42 | -7.65 | 0.36 | 39.09 |
| Cash EPS (Rs.) | -4.33 | -1.36 | 6.96 | 44.56 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 48.99 | 58.41 | 66.02 | 80.81 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 48.99 | 58.41 | 66.02 | 80.81 |
| Revenue From Operations / Share (Rs.) | 71.10 | 111.89 | 168.39 | 341.77 |
| PBDIT / Share (Rs.) | -0.19 | 7.92 | 18.27 | 65.87 |
| PBIT / Share (Rs.) | -5.37 | 1.51 | 11.11 | 60.20 |
| PBT / Share (Rs.) | -12.03 | -8.20 | 2.01 | 51.61 |
| Net Profit / Share (Rs.) | -9.51 | -7.77 | -0.20 | 38.89 |
| NP After MI And SOA / Share (Rs.) | -9.51 | -7.77 | -0.20 | 38.89 |
| PBDIT Margin (%) | -0.27 | 7.07 | 10.84 | 19.27 |
| PBIT Margin (%) | -7.55 | 1.34 | 6.59 | 17.61 |
| PBT Margin (%) | -16.91 | -7.33 | 1.19 | 15.10 |
| Net Profit Margin (%) | -13.36 | -6.94 | -0.11 | 11.37 |
| NP After MI And SOA Margin (%) | -13.36 | -6.94 | -0.11 | 11.37 |
| Return on Networth / Equity (%) | -19.40 | -13.29 | -0.30 | 48.12 |
| Return on Capital Employeed (%) | -8.14 | 2.01 | 12.35 | 50.02 |
| Return On Assets (%) | -5.40 | -4.18 | -0.09 | 13.85 |
| Long Term Debt / Equity (X) | 0.29 | 0.18 | 0.23 | 0.25 |
| Total Debt / Equity (X) | 1.26 | 0.90 | 0.81 | 0.91 |
| Asset Turnover Ratio (%) | 0.39 | 0.55 | 0.77 | 0.00 |
| Current Ratio (X) | 1.15 | 1.24 | 1.15 | 1.16 |
| Quick Ratio (X) | 0.77 | 0.90 | 0.85 | 0.93 |
| Inventory Turnover Ratio (X) | 1.25 | 2.14 | 3.65 | 0.00 |
| Dividend Payout Ratio (NP) (%) | 0.00 | 0.00 | 0.00 | 2.57 |
| Dividend Payout Ratio (CP) (%) | 0.00 | 0.00 | 0.00 | 2.24 |
| Earning Retention Ratio (%) | 0.00 | 0.00 | 0.00 | 97.43 |
| Cash Earning Retention Ratio (%) | 0.00 | 0.00 | 0.00 | 97.76 |
| Interest Coverage Ratio (X) | -0.02 | 0.94 | 2.01 | 7.67 |
| Interest Coverage Ratio (Post Tax) (X) | -0.42 | 0.23 | 0.97 | 5.53 |
| Enterprise Value (Cr.) | 106.47 | 122.38 | 163.11 | 313.54 |
| EV / Net Operating Revenue (X) | 1.15 | 0.83 | 0.74 | 0.88 |
| EV / EBITDA (X) | -416.21 | 11.83 | 6.84 | 4.59 |
| MarketCap / Net Operating Revenue (X) | 0.31 | 0.40 | 0.45 | 0.68 |
| Retention Ratios (%) | 0.00 | 0.00 | 0.00 | 97.42 |
| Price / BV (X) | 0.46 | 0.77 | 1.15 | 2.90 |
| Price / Net Operating Revenue (X) | 0.31 | 0.40 | 0.45 | 0.68 |
| EarningsYield | -0.41 | -0.17 | 0.00 | 0.16 |
After reviewing the key financial ratios for ANG Lifesciences India Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is -9.42. This value is below the healthy minimum of 5. It has decreased from -7.65 (Mar 24) to -9.42, marking a decrease of 1.77.
- For Diluted EPS (Rs.), as of Mar 25, the value is -9.42. This value is below the healthy minimum of 5. It has decreased from -7.65 (Mar 24) to -9.42, marking a decrease of 1.77.
- For Cash EPS (Rs.), as of Mar 25, the value is -4.33. This value is below the healthy minimum of 3. It has decreased from -1.36 (Mar 24) to -4.33, marking a decrease of 2.97.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 48.99. It has decreased from 58.41 (Mar 24) to 48.99, marking a decrease of 9.42.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 48.99. It has decreased from 58.41 (Mar 24) to 48.99, marking a decrease of 9.42.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 71.10. It has decreased from 111.89 (Mar 24) to 71.10, marking a decrease of 40.79.
- For PBDIT / Share (Rs.), as of Mar 25, the value is -0.19. This value is below the healthy minimum of 2. It has decreased from 7.92 (Mar 24) to -0.19, marking a decrease of 8.11.
- For PBIT / Share (Rs.), as of Mar 25, the value is -5.37. This value is below the healthy minimum of 0. It has decreased from 1.51 (Mar 24) to -5.37, marking a decrease of 6.88.
- For PBT / Share (Rs.), as of Mar 25, the value is -12.03. This value is below the healthy minimum of 0. It has decreased from -8.20 (Mar 24) to -12.03, marking a decrease of 3.83.
- For Net Profit / Share (Rs.), as of Mar 25, the value is -9.51. This value is below the healthy minimum of 2. It has decreased from -7.77 (Mar 24) to -9.51, marking a decrease of 1.74.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is -9.51. This value is below the healthy minimum of 2. It has decreased from -7.77 (Mar 24) to -9.51, marking a decrease of 1.74.
- For PBDIT Margin (%), as of Mar 25, the value is -0.27. This value is below the healthy minimum of 10. It has decreased from 7.07 (Mar 24) to -0.27, marking a decrease of 7.34.
- For PBIT Margin (%), as of Mar 25, the value is -7.55. This value is below the healthy minimum of 10. It has decreased from 1.34 (Mar 24) to -7.55, marking a decrease of 8.89.
- For PBT Margin (%), as of Mar 25, the value is -16.91. This value is below the healthy minimum of 10. It has decreased from -7.33 (Mar 24) to -16.91, marking a decrease of 9.58.
- For Net Profit Margin (%), as of Mar 25, the value is -13.36. This value is below the healthy minimum of 5. It has decreased from -6.94 (Mar 24) to -13.36, marking a decrease of 6.42.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is -13.36. This value is below the healthy minimum of 8. It has decreased from -6.94 (Mar 24) to -13.36, marking a decrease of 6.42.
- For Return on Networth / Equity (%), as of Mar 25, the value is -19.40. This value is below the healthy minimum of 15. It has decreased from -13.29 (Mar 24) to -19.40, marking a decrease of 6.11.
- For Return on Capital Employeed (%), as of Mar 25, the value is -8.14. This value is below the healthy minimum of 10. It has decreased from 2.01 (Mar 24) to -8.14, marking a decrease of 10.15.
- For Return On Assets (%), as of Mar 25, the value is -5.40. This value is below the healthy minimum of 5. It has decreased from -4.18 (Mar 24) to -5.40, marking a decrease of 1.22.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.29. This value is within the healthy range. It has increased from 0.18 (Mar 24) to 0.29, marking an increase of 0.11.
- For Total Debt / Equity (X), as of Mar 25, the value is 1.26. This value exceeds the healthy maximum of 1. It has increased from 0.90 (Mar 24) to 1.26, marking an increase of 0.36.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.39. It has decreased from 0.55 (Mar 24) to 0.39, marking a decrease of 0.16.
- For Current Ratio (X), as of Mar 25, the value is 1.15. This value is below the healthy minimum of 1.5. It has decreased from 1.24 (Mar 24) to 1.15, marking a decrease of 0.09.
- For Quick Ratio (X), as of Mar 25, the value is 0.77. This value is below the healthy minimum of 1. It has decreased from 0.90 (Mar 24) to 0.77, marking a decrease of 0.13.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 1.25. This value is below the healthy minimum of 4. It has decreased from 2.14 (Mar 24) to 1.25, marking a decrease of 0.89.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Interest Coverage Ratio (X), as of Mar 25, the value is -0.02. This value is below the healthy minimum of 3. It has decreased from 0.94 (Mar 24) to -0.02, marking a decrease of 0.96.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is -0.42. This value is below the healthy minimum of 3. It has decreased from 0.23 (Mar 24) to -0.42, marking a decrease of 0.65.
- For Enterprise Value (Cr.), as of Mar 25, the value is 106.47. It has decreased from 122.38 (Mar 24) to 106.47, marking a decrease of 15.91.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.15. This value is within the healthy range. It has increased from 0.83 (Mar 24) to 1.15, marking an increase of 0.32.
- For EV / EBITDA (X), as of Mar 25, the value is -416.21. This value is below the healthy minimum of 5. It has decreased from 11.83 (Mar 24) to -416.21, marking a decrease of 428.04.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.31. This value is below the healthy minimum of 1. It has decreased from 0.40 (Mar 24) to 0.31, marking a decrease of 0.09.
- For Retention Ratios (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 30. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Price / BV (X), as of Mar 25, the value is 0.46. This value is below the healthy minimum of 1. It has decreased from 0.77 (Mar 24) to 0.46, marking a decrease of 0.31.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.31. This value is below the healthy minimum of 1. It has decreased from 0.40 (Mar 24) to 0.31, marking a decrease of 0.09.
- For EarningsYield, as of Mar 25, the value is -0.41. This value is below the healthy minimum of 5. It has decreased from -0.17 (Mar 24) to -0.41, marking a decrease of 0.24.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
Unable to fetch valid data for stock valuation.Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in ANG Lifesciences India Ltd:
- Net Profit Margin: -13.36%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: -8.14% (Industry Average ROCE: 16.24%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: -19.4% (Industry Average ROE: 14.95%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): -0.42
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.77
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 52.67)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 1.26
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: -13.36%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Darbara Complex, Amritsar Punjab 143001 | cs@anglifesciences.com http://www.anglifesciences.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Rajesh Gupta | Managing Director |
| Mrs. Saruchi Gupta | Whole Time Director |
| Mr. Rohit Mittal | Non Executive Director |
| Mr. Sukhpal Singh | Independent Director |
| Mr. Harvinder Singh | Independent Director |
| Mrs. Chetna | Independent Director |

